Published in Aliment Pharmacol Ther on July 01, 2004
Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) (2012) 4.04
Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci (2010) 3.72
Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. Gastroenterology (2006) 3.53
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology (2006) 2.08
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol (2010) 2.06
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer (2010) 2.04
Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol (2009) 1.68
Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring) (2010) 1.64
Treatment of non-alcoholic fatty liver disease. Postgrad Med J (2006) 1.63
Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol (2007) 1.59
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2008) 1.54
Treatment of nonalcoholic fatty liver disease. World J Gastroenterol (2006) 1.27
Metformin prevents endotoxin-induced liver injury after partial hepatectomy. J Pharmacol Exp Ther (2005) 1.12
Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol (2015) 1.11
Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol (2010) 1.11
Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology (2013) 1.10
The role of metformin in the management of NAFLD. Exp Diabetes Res (2011) 1.09
Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol (2010) 1.07
Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol (2014) 1.05
Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol (2010) 1.03
Silymarin in non alcoholic fatty liver disease. World J Hepatol (2013) 1.03
Gastrointestinal complications of diabetes mellitus. World J Diabetes (2013) 1.03
The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr (2009) 1.03
The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci (2007) 0.97
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci (2011) 0.96
Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World J Hepatol (2014) 0.96
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci (2013) 0.94
Mitochondrial dysfunction: a basic mechanism in inflammation-related non-communicable diseases and therapeutic opportunities. Mediators Inflamm (2013) 0.93
Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev (2014) 0.92
Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc (2015) 0.90
The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial. Hepat Mon (2013) 0.90
Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. World J Gastroenterol (2014) 0.87
Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly. Curr Gerontol Geriatr Res (2011) 0.86
Advances in the treatment of nonalcoholic fatty liver disease. Ther Adv Endocrinol Metab (2010) 0.86
Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications (2007) 0.86
Evidence for AMPK-dependent regulation of exocytosis of lipoproteins in a model liver cell line. Exp Cell Res (2008) 0.86
An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). Ther Adv Endocrinol Metab (2011) 0.86
Non-alcohol fatty liver disease in Asia: Prevention and planning. World J Hepatol (2015) 0.85
Metformin and metabolic diseases: a focus on hepatic aspects. Front Med (2015) 0.83
Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease. Int J Hepatol (2012) 0.83
Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol (2015) 0.83
Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review. World J Gastroenterol (2006) 0.82
Non-alcoholic fatty liver disease in the Philippines: comparable with other nations? World J Gastroenterol (2008) 0.82
Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes. J Investig Med (2012) 0.81
Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. J Clin Exp Hepatol (2012) 0.81
Pharmacotherapy for Nonalcoholic Fatty Liver Disease. Semin Liver Dis (2015) 0.81
Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol (2016) 0.81
Systematic review: Preventive and therapeutic applications of metformin in liver disease. World J Hepatol (2015) 0.79
Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers. Sci Rep (2015) 0.78
Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD). Nutrients (2017) 0.78
The therapy of insulin resistance in other diseases besides type 2 diabetes. Eat Weight Disord (2014) 0.77
Treatment options for nonalcoholic Fatty liver disease. Therap Adv Gastroenterol (2008) 0.77
Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome. Int J Endocrinol (2015) 0.76
Current and novel therapies for the treatment of nonalcoholic steatohepatitis. Hepatol Int (2007) 0.76
Treatment of nonalcoholic steatohepatitis in adults: present and future. Gastroenterol Res Pract (2015) 0.76
Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis. Diabetes (2015) 0.76
Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD). Am J Transl Res (2016) 0.76
Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment. Gastroenterol Hepatol (N Y) (2006) 0.75
Dapagliflozin-Induced Acute-on-Chronic Liver Injury. ACG Case Rep J (2016) 0.75
Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Gastroenterol Res Pract (2017) 0.75
Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase. J Diabetes Complications (2017) 0.75
Open-access endoscopy service for general practitioners. Br Med J (1979) 6.07
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell (2001) 5.19
Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med (2000) 5.13
A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med (1995) 4.84
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med (1989) 4.69
Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology (1999) 4.59
Leptin regulates proinflammatory immune responses. FASEB J (1998) 4.31
Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med (1989) 4.07
Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A (1997) 3.79
Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med (2000) 3.47
Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst (1999) 3.46
Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res (1998) 3.36
A 30-kDa alternative translation product of the CCAAT/enhancer binding protein alpha message: transcriptional activator lacking antimitotic activity. Proc Natl Acad Sci U S A (1993) 3.33
Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J (1999) 3.18
Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med (1992) 3.01
Animal models of steatosis. Semin Liver Dis (2001) 2.88
Myosarcomas of the stomach: natural history, prognostic factors and management. Cancer (1982) 2.85
Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am J Physiol (1992) 2.33
Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med (1989) 2.28
The hedgehog pathway regulates remodelling responses to biliary obstruction in rats. Gut (2008) 2.26
Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology (1993) 2.20
Transtracheal oxygen delivery and patients with chronic obstructive pulmonary disease. Respir Med (1989) 2.19
Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. Hepatology (2001) 2.14
Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology (2001) 2.13
Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA (1999) 2.12
Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology (2000) 2.10
Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis (1995) 2.07
GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell (1998) 2.03
Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. Am J Clin Pathol (1995) 2.00
Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem (1999) 1.94
Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group (No. 119) Hepatology (1991) 1.78
Anorectal melanoma. Cancer (1981) 1.77
Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys (2000) 1.74
Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology (2000) 1.63
FAO/WHO scientific update on carbohydrates in human nutrition: conclusions. Eur J Clin Nutr (2007) 1.60
Axonal transport of actin in rabbit retinal ganglion cells. J Cell Biol (1979) 1.52
Forebrain activation in REM sleep: an FDG PET study. Brain Res (1997) 1.46
Septic arthritis caused by Propionibacterium acnes. JAMA (1982) 1.45
Impaired liver regeneration in inducible nitric oxide synthasedeficient mice. Proc Natl Acad Sci U S A (1998) 1.44
Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis. Gastroenterology (1993) 1.43
Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res (2001) 1.42
Hepatitis B e antigen, DNA polymerase activity, and infection of household contacts with hepatitis B virus. Gastroenterology (1979) 1.42
Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut (2004) 1.42
Nervous system involvement in type IV glycogenosis. Arch Pathol Lab Med (1979) 1.40
Kupffer cell depletion by CI2MDP-liposomes alters hepatic cytokine expression and delays liver regeneration after partial hepatectomy. Liver (2000) 1.39
Myosarcomas of the small and large intestine: a clinicopathologic study. J Surg Oncol (1983) 1.39
Tumor necrosis factor increases mitochondrial oxidant production and induces expression of uncoupling protein-2 in the regenerating mice [correction of rat] liver. Hepatology (1999) 1.34
Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology (1999) 1.33
Phenotypic abnormalities in macrophages from leptin-deficient, obese mice. Am J Physiol (1999) 1.32
Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol (2003) 1.31
Colonic tuberculosis diagnosed by colonoscopic biopsy. Gastroenterology (1979) 1.30
Comparison of culture and serology for the diagnosis of cytomegalovirus infection in kidney and liver transplant recipients. J Infect Dis (1990) 1.29
Lipids up-regulate uncoupling protein 2 expression in rat hepatocytes. Gastroenterology (1999) 1.27
Kupffer cell depletion by gadolinium chloride enhances liver regeneration after partial hepatectomy in rats. Am J Physiol (1996) 1.25
Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology (1998) 1.22
Tumor necrosis factor alpha promotes nuclear localization of cytokine-inducible CCAAT/enhancer binding protein isoforms in hepatocytes. J Biol Chem (1996) 1.22
Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. J Biol Chem (1998) 1.22
Glycaemia, arterial pressure and micro-albuminuria in type 1 (insulin-dependent) diabetes mellitus. Diabetologia (1984) 1.22
Cytokines and alcoholic liver disease. Semin Liver Dis (1993) 1.20
Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther (1994) 1.20
Quantitative comparison and evaluation of software packages for assessment of abdominal adipose tissue distribution by magnetic resonance imaging. Int J Obes (Lond) (2007) 1.18
Vitamin E therapy of acute CCl4-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding. Hepatology (1995) 1.18
Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation. Am J Physiol Gastrointest Liver Physiol (2001) 1.16
Lethal tricuspid and mitral regurgitation in Marfan's syndrome. Am J Cardiol (1967) 1.16
Chronic ethanol consumption induces the production of tumor necrosis factor-alpha and related cytokines in liver and adipose tissue. Alcohol Clin Exp Res (1998) 1.15
Kupffer cell depletion abolishes induction of interleukin-10 and permits sustained overexpression of tumor necrosis factor alpha messenger RNA in the regenerating rat liver. Hepatology (1997) 1.14
Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol (2001) 1.12
Major differences in the IgG subclass response to Helicobacter pylori in the first and third worlds. Scand J Gastroenterol (2002) 1.11
Hepatitis B virus DNA in peripheral-blood mononuclear cells in chronic hepatitis B after HBsAg clearance. Hepatology (1992) 1.10
Quantitation of hepatitis B viral DNA by solution hybridization: comparison with DNA polymerase and hepatitis B e antigen during antiviral therapy. J Med Virol (1989) 1.09
Effects of chronic ethanol consumption on cytokine regulation of liver regeneration. Am J Physiol (1998) 1.06
Breath biomarkers and non-alcoholic fatty liver disease: preliminary observations. Biomarkers (2006) 1.05
Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci (1997) 1.04
Alcohol and dietary intake in the development of chronic pancreatitis and liver disease in alcoholism. Am J Clin Nutr (1988) 1.02
Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann Intern Med (1986) 1.01
Insulin resistance and steatosis in hepatitis C virus infection. Gut (2005) 1.00
Tape recorder for evaluation of coughs in children. Am J Dis Child (1966) 0.98
Image-guided core-needle breast biopsy is an accurate technique to evaluate patients with nonpalpable imaging abnormalities. Ann Surg (1998) 0.98
Desquamative interstitial pneumonia. An electron microscopic study. Am J Pathol (1970) 0.98
Alcoholic liver disease presenting with marked elevation of serum alkaline phosphatase. A combined clinical and pathological study. Am J Dig Dis (1978) 0.97
Administration of a mixture of fungal glucosidases to a patient with type II glycogenosis (Pompe's disease). Pediatrics (1968) 0.97
A study of patient acceptance of double-contrast barium enema and colonoscopy. Which procedure is preferred by patients? Arch Intern Med (1987) 0.96
Acute non-A, non-B hepatitis with serum sickness-like syndrome and aplastic anemia. JAMA (1981) 0.96
Relationship between pyridoxal 5'-phosphate deficiency and aminotransferase levels in alcoholic hepatitis. Gastroenterology (1984) 0.96
Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer (1994) 0.95
Comparative efficacy of adenine arabinoside 5' monophosphate and prednisone withdrawal followed by adenine arabinoside 5' monophosphate in the treatment of chronic active hepatitis type B. Gastroenterology (1985) 0.95
An approach to salvage a "frozen" pacing lead. Pacing Clin Electrophysiol (2000) 0.95
Spontaneous clearance and reactivation of hepatitis B virus infection among male homosexuals with chronic type B hepatitis. Ann Intern Med (1984) 0.94
Two-stage palliative surgical approach for pulmonary atresia with intact ventricular septum (type I). Am J Cardiol (1972) 0.94
Gadolinium chloride alters the acinar distribution of phagocytosis and balance between pro- and anti-inflammatory cytokines. Shock (1996) 0.93
Nodular regenerative hyperplasia: a controversial indication for orthotopic liver transplantation. Transpl Int (1994) 0.93
Factors influencing response to interferon in chronic hepatitis B: implications for Asian and western populations. Hepatology (1990) 0.93
Irradiation-induced chondrosarcoma. A case report. J Bone Joint Surg Am (1976) 0.92
Anti-hepatitis B core immunoglobulin M in the serologic evaluation of hepatitis B virus infection and simultaneous infection with type B, delta agent, and non-A, non-B viruses. Gastroenterology (1983) 0.92
Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology (2001) 0.92
Genomic variations in the hepatitis B core gene: a possible factor influencing response to interferon alfa treatment. Gastroenterology (1995) 0.92
Bacterial endocarditis due to penicillin-resistant Streptococcus viridans. Clin Pediatr (Phila) (1979) 0.91
Brunner's gland cystadenoma of the duodenum. Am J Surg (1973) 0.91